10-Q 1 form10-q.htm
0001138978 false --08-31 Q3 http://fasb.org/us-gaap/2023#RelatedPartyMember http://fasb.org/us-gaap/2023#RelatedPartyMember P3Y P5Y 0001138978 2022-09-01 2023-05-31 0001138978 2023-07-17 0001138978 2023-05-31 0001138978 2022-08-31 0001138978 2023-03-01 2023-05-31 0001138978 2022-03-01 2022-05-31 0001138978 2021-09-01 2022-05-31 0001138978 us-gaap:CommonStockMember 2022-08-31 0001138978 us-gaap:AdditionalPaidInCapitalMember 2022-08-31 0001138978 NVOS:CommonStockToBeIssuedMember 2022-08-31 0001138978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-08-31 0001138978 us-gaap:RetainedEarningsMember 2022-08-31 0001138978 NVOS:TotalNovoStockholdersEquityMember 2022-08-31 0001138978 us-gaap:NoncontrollingInterestMember 2022-08-31 0001138978 us-gaap:CommonStockMember 2022-11-30 0001138978 us-gaap:AdditionalPaidInCapitalMember 2022-11-30 0001138978 NVOS:CommonStockToBeIssuedMember 2022-11-30 0001138978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-11-30 0001138978 us-gaap:RetainedEarningsMember 2022-11-30 0001138978 NVOS:TotalNovoStockholdersEquityMember 2022-11-30 0001138978 us-gaap:NoncontrollingInterestMember 2022-11-30 0001138978 2022-11-30 0001138978 us-gaap:CommonStockMember 2023-02-28 0001138978 us-gaap:AdditionalPaidInCapitalMember 2023-02-28 0001138978 NVOS:CommonStockToBeIssuedMember 2023-02-28 0001138978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-02-28 0001138978 us-gaap:RetainedEarningsMember 2023-02-28 0001138978 NVOS:TotalNovoStockholdersEquityMember 2023-02-28 0001138978 us-gaap:NoncontrollingInterestMember 2023-02-28 0001138978 2023-02-28 0001138978 us-gaap:CommonStockMember 2021-08-31 0001138978 us-gaap:AdditionalPaidInCapitalMember 2021-08-31 0001138978 NVOS:CommonStockToBeIssuedMember 2021-08-31 0001138978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-08-31 0001138978 us-gaap:RetainedEarningsMember 2021-08-31 0001138978 NVOS:TotalNovoStockholdersEquityMember 2021-08-31 0001138978 us-gaap:NoncontrollingInterestMember 2021-08-31 0001138978 2021-08-31 0001138978 us-gaap:CommonStockMember 2021-11-30 0001138978 us-gaap:AdditionalPaidInCapitalMember 2021-11-30 0001138978 NVOS:CommonStockToBeIssuedMember 2021-11-30 0001138978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-11-30 0001138978 us-gaap:RetainedEarningsMember 2021-11-30 0001138978 NVOS:TotalNovoStockholdersEquityMember 2021-11-30 0001138978 us-gaap:NoncontrollingInterestMember 2021-11-30 0001138978 2021-11-30 0001138978 us-gaap:CommonStockMember 2022-02-28 0001138978 us-gaap:AdditionalPaidInCapitalMember 2022-02-28 0001138978 NVOS:CommonStockToBeIssuedMember 2022-02-28 0001138978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-02-28 0001138978 us-gaap:RetainedEarningsMember 2022-02-28 0001138978 NVOS:TotalNovoStockholdersEquityMember 2022-02-28 0001138978 us-gaap:NoncontrollingInterestMember 2022-02-28 0001138978 2022-02-28 0001138978 us-gaap:CommonStockMember 2022-09-01 2022-11-30 0001138978 us-gaap:AdditionalPaidInCapitalMember 2022-09-01 2022-11-30 0001138978 NVOS:CommonStockToBeIssuedMember 2022-09-01 2022-11-30 0001138978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-01 2022-11-30 0001138978 us-gaap:RetainedEarningsMember 2022-09-01 2022-11-30 0001138978 NVOS:TotalNovoStockholdersEquityMember 2022-09-01 2022-11-30 0001138978 us-gaap:NoncontrollingInterestMember 2022-09-01 2022-11-30 0001138978 2022-09-01 2022-11-30 0001138978 us-gaap:CommonStockMember 2022-12-01 2023-02-28 0001138978 us-gaap:AdditionalPaidInCapitalMember 2022-12-01 2023-02-28 0001138978 NVOS:CommonStockToBeIssuedMember 2022-12-01 2023-02-28 0001138978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-01 2023-02-28 0001138978 us-gaap:RetainedEarningsMember 2022-12-01 2023-02-28 0001138978 NVOS:TotalNovoStockholdersEquityMember 2022-12-01 2023-02-28 0001138978 us-gaap:NoncontrollingInterestMember 2022-12-01 2023-02-28 0001138978 2022-12-01 2023-02-28 0001138978 us-gaap:CommonStockMember 2023-03-01 2023-05-31 0001138978 us-gaap:AdditionalPaidInCapitalMember 2023-03-01 2023-05-31 0001138978 NVOS:CommonStockToBeIssuedMember 2023-03-01 2023-05-31 0001138978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-01 2023-05-31 0001138978 us-gaap:RetainedEarningsMember 2023-03-01 2023-05-31 0001138978 NVOS:TotalNovoStockholdersEquityMember 2023-03-01 2023-05-31 0001138978 us-gaap:NoncontrollingInterestMember 2023-03-01 2023-05-31 0001138978 us-gaap:CommonStockMember 2021-09-01 2021-11-30 0001138978 us-gaap:AdditionalPaidInCapitalMember 2021-09-01 2021-11-30 0001138978 NVOS:CommonStockToBeIssuedMember 2021-09-01 2021-11-30 0001138978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-09-01 2021-11-30 0001138978 us-gaap:RetainedEarningsMember 2021-09-01 2021-11-30 0001138978 NVOS:TotalNovoStockholdersEquityMember 2021-09-01 2021-11-30 0001138978 us-gaap:NoncontrollingInterestMember 2021-09-01 2021-11-30 0001138978 2021-09-01 2021-11-30 0001138978 us-gaap:CommonStockMember 2021-12-01 2022-02-28 0001138978 us-gaap:AdditionalPaidInCapitalMember 2021-12-01 2022-02-28 0001138978 NVOS:CommonStockToBeIssuedMember 2021-12-01 2022-02-28 0001138978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-01 2022-02-28 0001138978 us-gaap:RetainedEarningsMember 2021-12-01 2022-02-28 0001138978 NVOS:TotalNovoStockholdersEquityMember 2021-12-01 2022-02-28 0001138978 us-gaap:NoncontrollingInterestMember 2021-12-01 2022-02-28 0001138978 2021-12-01 2022-02-28 0001138978 us-gaap:CommonStockMember 2022-03-01 2022-05-31 0001138978 us-gaap:AdditionalPaidInCapitalMember 2022-03-01 2022-05-31 0001138978 NVOS:CommonStockToBeIssuedMember 2022-03-01 2022-05-31 0001138978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-01 2022-05-31 0001138978 us-gaap:RetainedEarningsMember 2022-03-01 2022-05-31 0001138978 NVOS:TotalNovoStockholdersEquityMember 2022-03-01 2022-05-31 0001138978 us-gaap:NoncontrollingInterestMember 2022-03-01 2022-05-31 0001138978 us-gaap:CommonStockMember 2023-05-31 0001138978 us-gaap:AdditionalPaidInCapitalMember 2023-05-31 0001138978 NVOS:CommonStockToBeIssuedMember 2023-05-31 0001138978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-05-31 0001138978 us-gaap:RetainedEarningsMember 2023-05-31 0001138978 NVOS:TotalNovoStockholdersEquityMember 2023-05-31 0001138978 us-gaap:NoncontrollingInterestMember 2023-05-31 0001138978 us-gaap:CommonStockMember 2022-05-31 0001138978 us-gaap:AdditionalPaidInCapitalMember 2022-05-31 0001138978 NVOS:CommonStockToBeIssuedMember 2022-05-31 0001138978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-05-31 0001138978 us-gaap:RetainedEarningsMember 2022-05-31 0001138978 NVOS:TotalNovoStockholdersEquityMember 2022-05-31 0001138978 us-gaap:NoncontrollingInterestMember 2022-05-31 0001138978 2022-05-31 0001138978 NVOS:ShareExchangeAgreementMember NVOS:NHLMember 2017-04-23 2017-04-25 0001138978 srt:ParentCompanyMember 2017-05-07 2017-05-09 0001138978 NVOS:PeriodEndMember 2023-05-31 0001138978 NVOS:PeriodEndMember 2022-05-31 0001138978 NVOS:PeriodEndMember 2022-08-31 0001138978 NVOS:AveragePeriodMember 2023-05-31 0001138978 NVOS:AveragePeriodMember 2022-05-31 0001138978 NVOS:AveragePeriodMember 2022-08-31 0001138978 NVOS:TerragenxIncMember 2022-08-31 0001138978 NVOS:OneThousandTwoHundredEightyFiveCanadaCorpMember 2022-08-31 0001138978 NVOS:NovoHealthnetKemptvilleCentreIncMember 2022-08-31 0001138978 NVOS:NovoEarthTherapeuticsIncMember 2022-08-31 0001138978 2021-12-01 2022-08-31 0001138978 NVOS:OptionsOrWarrantsOutstandingMember 2022-09-01 2023-05-31 0001138978 NVOS:OptionsOrWarrantsOutstandingMember 2021-09-01 2022-05-31 0001138978 us-gaap:CommonStockMember 2022-09-01 2023-05-31 0001138978 NVOS:CommonStockToBeIssuedMember 2022-09-01 2023-05-31 0001138978 2021-09-01 2022-08-31 0001138978 us-gaap:BuildingMember 2023-05-31 0001138978 us-gaap:LeaseholdImprovementsMember 2023-05-31 0001138978 NVOS:ClinicalEquipmentMember 2023-05-31 0001138978 us-gaap:ComputerEquipmentMember 2023-05-31 0001138978 us-gaap:OfficeEquipmentMember 2023-05-31 0001138978 us-gaap:FurnitureAndFixturesMember 2023-05-31 0001138978 NVOS:LandUseRightsMember 2023-05-31 0001138978 us-gaap:IntellectualPropertyMember 2023-05-31 0001138978 us-gaap:CustomerRelationshipsMember 2023-05-31 0001138978 NVOS:BrandNamesMember 2023-05-31 0001138978 NVOS:ApkaHealthIncMember 2021-08-31 0001138978 NVOS:ExecutiveFitnessLeadersMember 2021-08-31 0001138978 NVOS:RocklandMember 2021-08-31 0001138978 NVOS:AcenziaIncMember 2021-08-31 0001138978 NVOS:OneThousandTwoHundredEightyFiveCanadaCorpMember 2021-08-31 0001138978 NVOS:ApkaHealthIncMember 2021-09-01 2022-08-31 0001138978 NVOS:ExecutiveFitnessLeadersMember 2021-09-01 2022-08-31 0001138978 NVOS:RocklandMember 2021-09-01 2022-08-31 0001138978 NVOS:AcenziaIncMember 2021-09-01 2022-08-31 0001138978 NVOS:OneThousandTwoHundredEightyFiveCanadaCorpMember 2021-09-01 2022-08-31 0001138978 NVOS:ApkaHealthIncMember 2022-08-31 0001138978 NVOS:ExecutiveFitnessLeadersMember 2022-08-31 0001138978 NVOS:RocklandMember 2022-08-31 0001138978 NVOS:AcenziaIncMember 2022-08-31 0001138978 NVOS:OneThousandTwoHundredEightyFiveCanadaCorpMember 2022-08-31 0001138978 NVOS:ApkaHealthIncMember 2022-09-01 2023-05-31 0001138978 NVOS:ExecutiveFitnessLeadersMember 2022-09-01 2023-05-31 0001138978 NVOS:RocklandMember 2022-09-01 2023-05-31 0001138978 NVOS:AcenziaIncMember 2022-09-01 2023-05-31 0001138978 NVOS:OneThousandTwoHundredEightyFiveCanadaCorpMember 2022-09-01 2023-05-31 0001138978 NVOS:ApkaHealthIncMember 2023-05-31 0001138978 NVOS:ExecutiveFitnessLeadersMember 2023-05-31 0001138978 NVOS:RocklandMember 2023-05-31 0001138978 NVOS:AcenziaIncMember 2023-05-31 0001138978 NVOS:OneThousandTwoHundredEightyFiveCanadaCorpMember 2023-05-31 0001138978 us-gaap:RelatedPartyMember 2023-05-31 0001138978 us-gaap:RelatedPartyMember 2022-08-31 0001138978 NVOS:NonInterestBearingMember us-gaap:RelatedPartyMember 2023-05-31 0001138978 NVOS:SixPercentInterestRateMember us-gaap:RelatedPartyMember 2023-05-31 0001138978 NVOS:SixPercentInterestRateMember 2022-09-01 2023-05-31 0001138978 NVOS:ThirteenPointSevenFivePercentInterestRateMember us-gaap:RelatedPartyMember 2023-05-31 0001138978 NVOS:ThirteenPointSevenFivePercentInterestRateMember 2022-09-01 2023-05-31 0001138978 NVOS:NonInterestBearingMember us-gaap:RelatedPartyMember 2022-08-31 0001138978 NVOS:SixPercentInterestRateMember us-gaap:RelatedPartyMember 2022-08-31 0001138978 NVOS:SixPercentInterestRateMember 2021-09-01 2022-08-31 0001138978 NVOS:ThirteenPointSevenFivePercentInterestRateMember us-gaap:RelatedPartyMember 2022-08-31 0001138978 NVOS:ThirteenPointSevenFivePercentInterestRateMember 2021-09-01 2022-08-31 0001138978 NVOS:AdvanceToCorporationOneMember 2023-05-31 0001138978 NVOS:AdvanceToCorporationOneMember 2022-08-31 0001138978 NVOS:AdvanceToCorporationTwoMember 2023-05-31 0001138978 NVOS:AdvanceToCorporationTwoMember 2022-08-31 0001138978 NVOS:AdvanceToCorporationThreeMember 2023-05-31 0001138978 NVOS:AdvanceToCorporationThreeMember 2022-08-31 0001138978 NVOS:AdvanceToCorporationOneMember 2022-09-01 2023-05-31 0001138978 NVOS:AdvanceToCorporationOneMember 2021-09-01 2022-08-31 0001138978 NVOS:AdvanceToCorporationTwoMember 2022-09-01 2023-05-31 0001138978 NVOS:AdvanceToCorporationTwoMember 2021-09-01 2022-08-31 0001138978 NVOS:AdvanceToCorporationThreeMember 2022-09-01 2023-05-31 0001138978 NVOS:AdvanceToCorporationThreeMember 2021-09-01 2022-08-31 0001138978 us-gaap:LandMember 2023-05-31 0001138978 us-gaap:LandMember 2022-08-31 0001138978 us-gaap:BuildingMember 2022-08-31 0001138978 us-gaap:LeaseholdImprovementsMember 2022-08-31 0001138978 NVOS:ClinicalEquipmentMember 2022-08-31 0001138978 us-gaap:ComputerEquipmentMember 2022-08-31 0001138978 us-gaap:OfficeEquipmentMember 2022-08-31 0001138978 us-gaap:FurnitureAndFixturesMember 2022-08-31 0001138978 NVOS:LandUseRightsMember 2022-08-31 0001138978 us-gaap:IntellectualPropertyMember 2022-08-31 0001138978 us-gaap:CustomerRelationshipsMember 2022-08-31 0001138978 NVOS:BrandNamesMember 2022-08-31 0001138978 NVOS:NotesPayableOneMember 2023-05-31 0001138978 NVOS:NotesPayableOneMember 2022-08-31 0001138978 NVOS:NotesPayableTwoMember 2023-05-31 0001138978 NVOS:NotesPayableTwoMember 2022-08-31 0001138978 NVOS:NotesPayableThreeMember 2023-05-31 0001138978 NVOS:NotesPayableThreeMember 2022-08-31 0001138978 NVOS:NotesPayableFourMember 2023-05-31 0001138978 NVOS:NotesPayableFourMember 2022-08-31 0001138978 NVOS:NotesPayableFiveMember 2023-05-31 0001138978 NVOS:NotesPayableFiveMember 2022-08-31 0001138978 NVOS:CanadaEmergencyBusinessAccountLoanMember NVOS:TerragenxIncMember 2023-05-31 0001138978 NVOS:NotesPayableTwoMember 2022-09-01 2023-05-31 0001138978 NVOS:NotesPayableTwoMember 2021-09-01 2022-08-31 0001138978 NVOS:NotesPayableThreeMember 2022-09-01 2023-05-31 0001138978 NVOS:NotesPayableThreeMember 2021-09-01 2022-08-31 0001138978 NVOS:NotesPayableFourMember 2022-09-01 2023-05-31 0001138978 NVOS:NotesPayableFiveMember 2022-09-01 2023-05-31 0001138978 NVOS:CanadaEmergencyBusinessAccountLoanMember 2023-05-31 0001138978 NVOS:TwoConvertibleDebtMember 2021-12-14 0001138978 NVOS:ConvertibleDebtOneMember 2021-12-14 0001138978 NVOS:ConvertibleDebtTwoMember 2021-12-14 0001138978 NVOS:TwoConvertibleDebtMember 2021-12-13 2021-12-14 0001138978 us-gaap:MeasurementInputExpectedTermMember 2021-12-14 0001138978 us-gaap:MeasurementInputPriceVolatilityMember 2021-12-14 0001138978 us-gaap:MeasurementInputExpectedDividendRateMember 2021-12-14 0001138978 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-12-14 0001138978 us-gaap:ConvertibleDebtMember 2021-12-14 0001138978 us-gaap:WarrantMember 2021-12-14 0001138978 NVOS:ConvertibleDebtOneMember 2022-11-13 2022-11-14 0001138978 NVOS:ConvertibleDebtTwoMember 2022-11-13 2022-11-14 0001138978 NVOS:ConvertibleNotesMember 2022-11-13 2022-11-14 0001138978 NVOS:TwoConvertibleDebtMember 2022-11-14 0001138978 us-gaap:MeasurementInputExpectedTermMember 2022-11-13 2022-11-14 0001138978 us-gaap:MeasurementInputPriceVolatilityMember 2022-11-14 0001138978 us-gaap:MeasurementInputExpectedDividendRateMember 2022-11-14 0001138978 us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-11-14 0001138978 NVOS:TwoConvertibleDebtMember 2023-05-31 0001138978 NVOS:TwoConvertibleDebtMember 2022-09-01 2023-05-31 0001138978 NVOS:TwoConvertibleDebtMember 2022-08-31 0001138978 NVOS:TerragenxIncMember 2021-11-16 2021-11-17 0001138978 NVOS:TerragenxIncMember NVOS:TwoConvertibleDebtMember 2021-11-17 0001138978 NVOS:TerragenxIncMember NVOS:ConvertibleDebtOneMember 2021-11-17 0001138978 NVOS:TerragenxIncMember NVOS:ConvertibleDebtTwoMember 2021-11-17 0001138978 NVOS:TerragenxIncMember NVOS:TwoConvertibleDebtMember 2021-11-16 2021-11-17 0001138978 NVOS:PlatinumPointCapitalLLCMember NVOS:TwoConvertibleDebtMember 2022-06-01 2022-06-01 0001138978 NVOS:JeffersonStreetCapitalMember 2022-06-01 0001138978 us-gaap:MeasurementInputExpectedTermMember 2021-11-17 0001138978 us-gaap:MeasurementInputPriceVolatilityMember 2021-11-17 0001138978 us-gaap:MeasurementInputExpectedDividendRateMember 2021-11-17 0001138978 us-gaap:MeasurementInputRiskFreeInterestRateMember 2021-11-17 0001138978 NVOS:TerragenxIncMember us-gaap:ConvertibleDebtMember 2021-11-17 0001138978 NVOS:TerragenxIncMember us-gaap:WarrantMember 2021-11-17 0001138978 NVOS:JeffersonStreetCapitalMember 2022-12-02 2022-12-02 0001138978 NVOS:JeffersonStreetCapitalMember 2023-05-31 0001138978 NVOS:JeffersonStreetCapitalMember 2022-09-01 2023-05-31 0001138978 NVOS:MastHillSecuritiesPurchaseAgreementMember 2023-02-23 0001138978 NVOS:MastHillSecuritiesPurchaseAgreementMember 2023-02-23 2023-02-23 0001138978 NVOS:MastHillSecuritiesPurchaseAgreementMember srt:MaximumMember 2023-02-23 0001138978 NVOS:MastHillNoteAndMastHillWarrantMember 2023-02-23 2023-02-23 0001138978 NVOS:MastHillSecuritiesPurchaseAgreementMember srt:ScenarioForecastMember 2023-08-23 2023-08-23 0001138978 srt:ScenarioForecastMember NVOS:MastHillSecuritiesPurchaseAgreementMember 2023-09-23 2023-09-23 0001138978 srt:ScenarioForecastMember NVOS:MastHillSecuritiesPurchaseAgreementMember 2023-10-23 2023-10-23 0001138978 srt:ScenarioForecastMember NVOS:MastHillSecuritiesPurchaseAgreementMember 2023-11-23 2023-11-23 0001138978 srt:ScenarioForecastMember NVOS:MastHillSecuritiesPurchaseAgreementMember 2023-12-23 2023-12-23 0001138978 NVOS:MastHillSecuritiesPurchaseAgreementMember 2023-01-23 2023-01-23 0001138978 us-gaap:MeasurementInputExpectedTermMember 2023-02-23 0001138978 us-gaap:MeasurementInputPriceVolatilityMember 2023-02-23 0001138978 us-gaap:MeasurementInputExpectedDividendRateMember 2023-02-23 0001138978 us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-02-23 0001138978 NVOS:MastHillSecuritiesPurchaseAgreementMember us-gaap:ConvertibleDebtMember 2023-02-23 0001138978 NVOS:MastHillSecuritiesPurchaseAgreementMember us-gaap:CommonStockMember 2023-02-23 0001138978 NVOS:MastHillSecuritiesPurchaseAgreementMember us-gaap:WarrantMember 2023-02-23 0001138978 NVOS:MastHillSecuritiesPurchaseAgreementMember 2022-09-01 2023-05-31 0001138978 NVOS:MastHillSecuritiesPurchaseAgreementMember 2023-05-31 0001138978 NVOS:FirstFireGlobalOpportunitiesFundLLCSecuritiesPurchaseAgreementMember 2023-03-21 0001138978 NVOS:FirstFireGlobalOpportunitiesFundLLCSecuritiesPurchaseAgreementMember 2023-03-21 2023-03-21 0001138978 NVOS:FirstFireGlobalOpportunitiesFundLLCSecuritiesPurchaseAgreementMember srt:MaximumMember 2023-03-21 0001138978 NVOS:FirstFireNoteAndFirstFireWarrantMember 2023-03-21 2023-03-21 0001138978 NVOS:FirstFireGlobalOpportunitiesFundLLCSecuritiesPurchaseAgreementMember srt:ScenarioForecastMember 2023-09-21 2023-09-21 0001138978 srt:ScenarioForecastMember NVOS:FirstFireGlobalOpportunitiesFundLLCSecuritiesPurchaseAgreementMember 2023-10-21 2023-10-21 0001138978 srt:ScenarioForecastMember NVOS:FirstFireGlobalOpportunitiesFundLLCSecuritiesPurchaseAgreementMember 2023-11-21 2023-11-21 0001138978 srt:ScenarioForecastMember NVOS:FirstFireGlobalOpportunitiesFundLLCSecuritiesPurchaseAgreementMember 2023-12-21 2023-12-21 0001138978 srt:ScenarioForecastMember NVOS:FirstFireGlobalOpportunitiesFundLLCSecuritiesPurchaseAgreementMember 2024-01-21 2024-01-21 0001138978 NVOS:FirstFireGlobalOpportunitiesFundLLCSecuritiesPurchaseAgreementMember srt:ScenarioForecastMember 2024-02-21 2024-02-21 0001138978 us-gaap:MeasurementInputExpectedTermMember 2023-03-21 0001138978 us-gaap:MeasurementInputPriceVolatilityMember 2023-03-21 0001138978 us-gaap:MeasurementInputExpectedDividendRateMember 2023-03-21 0001138978 us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-03-21 0001138978 NVOS:FirstFireGlobalOpportunitiesFundLLCSecuritiesPurchaseAgreementMember us-gaap:ConvertibleDebtMember 2023-03-21 0001138978 NVOS:FirstFireGlobalOpportunitiesFundLLCSecuritiesPurchaseAgreementMember us-gaap:CommonStockMember 2023-03-21 0001138978 NVOS:FirstFireGlobalOpportunitiesFundLLCSecuritiesPurchaseAgreementMember us-gaap:WarrantMember 2023-03-21 0001138978 NVOS:FirstFireGlobalOpportunitiesFundLLCSecuritiesPurchaseAgreementMember 2022-09-01 2023-05-31 0001138978 NVOS:FirstFireGlobalOpportunitiesFundLLCSecuritiesPurchaseAgreementMember 2023-05-31 0001138978 NVOS:FiveDebenturesMember 2013-09-30 0001138978 NVOS:FiveDebenturesMember 2013-09-29 2013-09-30 0001138978 NVOS:FiveDebenturesMember 2017-11-29 2017-12-02 0001138978 NVOS:FiveDebenturesMember 2019-09-26 2019-09-27 0001138978 NVOS:FiveDebenturesMember 2021-11-01 2021-11-02 0001138978 NVOS:DebenturesMember 2018-01-29 2018-01-31 0001138978 NVOS:DebenturesMember 2018-01-31 0001138978 2020-07-20 2020-07-21 0001138978 us-gaap:WarrantMember 2022-09-01 2023-05-31 0001138978 NVOS:WarrantOneMember 2023-05-31 0001138978 NVOS:CommonStockOneMember 2022-09-01 2023-05-31 0001138978 NVOS:WarrantTwoMember 2023-05-31 0001138978 NVOS:CommonStockTwoMember 2022-09-01 2023-05-31 0001138978 us-gaap:WarrantMember srt:MinimumMember 2022-09-01 2023-05-31 0001138978 us-gaap:WarrantMember srt:MaximumMember 2022-09-01 2023-05-31 0001138978 us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2022-09-01 2023-05-31 0001138978 us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2022-09-01 2023-05-31 0001138978 us-gaap:WarrantMember 2023-05-31 0001138978 NVOS:ShareExchangeAgreementOneMember 2022-09-01 2023-05-31 0001138978 NVOS:HudsonBayMember 2022-09-01 2023-05-31 0001138978 NVOS:CVIMember 2022-09-01 2023-05-31 0001138978 NVOS:DebtHolderOneMember 2022-09-01 2023-05-31 0001138978 NVOS:DebtHolderTwoMember 2022-09-01 2023-05-31 0001138978 NVOS:DebtHolderThreeMember 2022-09-01 2023-05-31 0001138978 NVOS:WarrantHoldersOneMember 2023-01-05 0001138978 NVOS:WarrantHoldersOneMember 2023-01-05 2023-01-05 0001138978 NVOS:CVIMember 2023-01-05 2023-01-05 0001138978 NVOS:WarrantHoldersTwoMember 2023-01-12 0001138978 NVOS:WarrantHoldersTwoMember 2023-01-12 2023-01-12 0001138978 NVOS:WarrantHoldersThreeMember 2023-01-12 0001138978 NVOS:WarrantHoldersThreeMember 2023-01-12 2023-01-12 0001138978 NVOS:ShareExchangeAgreementTwoMember 2022-09-01 2023-05-31 0001138978 NVOS:ShareExchangeAgreementThreeMember 2022-09-01 2023-05-31 0001138978 NVOS:DebtHolderFourMember 2022-09-01 2023-05-31 0001138978 NVOS:DebtHolderFourMember 2023-03-06 2023-03-06 0001138978 NVOS:DebtHolderFourMember 2023-03-08 2023-03-08 0001138978 NVOS:WarrantholderFourMember 2023-03-17 0001138978 NVOS:WarrantholderFourMember 2023-03-17 2023-03-17 0001138978 NVOS:WarrantholderFiveMember 2023-03-17 0001138978 NVOS:WarrantholderFiveMember 2023-03-17 2023-03-17 0001138978 NVOS:SecuritiesPurchaseAgreementMember 2022-09-01 2023-05-31 0001138978 NVOS:WarrantholderSixMember 2023-05-10 0001138978 NVOS:WarrantholderSixMember 2023-05-10 2023-05-10 0001138978 NVOS:WarrantholderSevenMember 2023-05-11 0001138978 NVOS:WarrantholderSevenMember 2023-05-11 2023-05-11 0001138978 NVOS:TerragenxIncMember 2022-09-01 2023-05-31 0001138978 NVOS:TwoThousandAndFifteenIncentiveCompensationPlanMember srt:MaximumMember 2015-09-08 0001138978 NVOS:TwoThousandAndFifteenIncentiveCompensationPlanMember 2023-05-31 0001138978 NVOS:TwoThousandAndEighteenIncentiveCompensationPlanMember 2018-01-16 0001138978 NVOS:TwoThousandAndEighteenIncentivePlanMember 2023-05-31 0001138978 NVOS:TwoThousandAndTwentyOneEquityIncentivePlanMember 2021-02-09 0001138978 NVOS:TwoThousandAndTwentyOneEquityIncentivePlanMember 2021-02-09 2021-02-09 0001138978 NVOS:TwoThousandAndTwentyOneEquityIncentivePlanMember 2023-05-31 0001138978 NVOS:ExercisePriceRangeOneMember 2023-05-31 0001138978 NVOS:ExercisePriceRangeTwoMember 2023-05-31 0001138978 NVOS:ExercisePriceRangeThreeMember 2023-05-31 0001138978 NVOS:ExercisePriceRangeFourMember 2023-05-31 0001138978 NVOS:ExercisePriceRangeFiveMember 2023-05-31 0001138978 NVOS:ExercisePriceRangeSixMember 2023-05-31 0001138978 NVOS:ExercisePriceRangeSevenMember 2023-05-31 0001138978 NVOS:ExercisePriceRangeEightMember 2023-05-31 0001138978 srt:MinimumMember 2021-09-01 2022-05-31 0001138978 srt:MaximumMember 2021-09-01 2022-05-31 0001138978 NVOS:ExercisePriceRangeMember 2023-05-31 0001138978 NVOS:HealthCareServicesMember 2023-03-01 2023-05-31 0001138978 NVOS:HealthCareServicesMember 2022-03-01 2022-05-31 0001138978 NVOS:HealthCareServicesMember 2022-09-01 2023-05-31 0001138978 NVOS:HealthCareServicesMember 2021-09-01 2022-05-31 0001138978 NVOS:ProductManufacturingAndDevolopmentMember 2023-03-01 2023-05-31 0001138978 NVOS:ProductManufacturingAndDevolopmentMember 2022-03-01 2022-05-31 0001138978 NVOS:ProductManufacturingAndDevolopmentMember 2022-09-01 2023-05-31 0001138978 NVOS:ProductManufacturingAndDevolopmentMember 2021-09-01 2022-05-31 0001138978 us-gaap:CorporateMember 2023-03-01 2023-05-31 0001138978 us-gaap:CorporateMember 2022-03-01 2022-05-31 0001138978 us-gaap:CorporateMember 2022-09-01 2023-05-31 0001138978 us-gaap:CorporateMember 2021-09-01 2022-05-31 0001138978 NVOS:HealthCareServicesMember 2023-05-31 0001138978 NVOS:HealthCareServicesMember 2022-08-31 0001138978 NVOS:ProductManufacturingAndDevelopmentMember 2023-05-31 0001138978 NVOS:ProductManufacturingAndDevelopmentMember 2022-08-31 0001138978 us-gaap:CorporateMember 2023-05-31 0001138978 us-gaap:CorporateMember 2022-08-31 0001138978 NVOS:MastHillSecuritiesPurchaseAgreementMember us-gaap:SubsequentEventMember 2023-06-20 0001138978 NVOS:MastHillSecuritiesPurchaseAgreementMember us-gaap:SubsequentEventMember 2023-06-19 2023-06-20 0001138978 NVOS:MastHillSecuritiesPurchaseAgreementMember srt:MaximumMember us-gaap:SubsequentEventMember 2023-06-20 0001138978 NVOS:MastHillSecuritiesPurchaseAgreementMember srt:ScenarioForecastMember 2023-12-20 2023-12-20 0001138978 srt:ScenarioForecastMember NVOS:MastHillSecuritiesPurchaseAgreementMember 2024-01-20 2024-01-20 0001138978 srt:ScenarioForecastMember NVOS:MastHillSecuritiesPurchaseAgreementMember 2024-02-20 2024-02-20 0001138978 srt:ScenarioForecastMember NVOS:MastHillSecuritiesPurchaseAgreementMember 2024-03-20 2024-03-20 0001138978 srt:ScenarioForecastMember NVOS:MastHillSecuritiesPurchaseAgreementMember 2024-04-20 2024-04-20 0001138978 NVOS:MastHillSecuritiesPurchaseAgreementMember 2023-05-20 2023-05-20 0001138978 NVOS:TwoThousandTwentyOneEquityIncentivePlanMember us-gaap:SubsequentEventMember 2023-06-27 2023-06-28 0001138978 NVOS:ZsebokPartiesMember us-gaap:SubsequentEventMember 2023-06-27 2023-06-28 0001138978 NVOS:MrSethiMember us-gaap:SubsequentEventMember 2023-07-06 2023-07-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:CAD NVOS:Integer

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended May 31, 2023

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from ______, 20___, to _____, 20___.

 

Commission File Number 001-40089

 

Novo Integrated Sciences, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

Nevada   59-3691650

(State or Other Jurisdiction of

Incorporation or Organization)

 

(I.R.S. Employer

Identification Number)

 

11120 NE 2nd Street, Suite 100

Bellevue, Washington

  98004
(Address of Principal Executive Offices)   (Zip Code)

 

(206) 617-9797

(Registrant’s Telephone Number, Including Area Code)

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each Exchange on which Registered
Common Stock   NVOS   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
Emerging growth company    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

There were 148,434,184 shares of the Registrant’s $0.001 par value common stock outstanding as of July 17, 2023.

 

 

 

  

 

 

Novo Integrated Sciences, Inc.

 

Contents

 

PART I – FINANCIAL INFORMATION  
     
Item 1. Financial Statements 3
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 31
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 51
     
Item 4. Controls and Procedures 52
     
PART II – OTHER INFORMATION 52
     
Item 1. Legal Proceedings 52
     
Item 1A. Risk Factors 52
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 52
     
Item 3. Defaults Upon Senior Securities 52
     
Item 4. Mine Safety Disclosures 52
     
Item 5. Other Information 52
     
Item 6. Exhibits 53
     
Signatures 54

 

2
 

 

Item 1. Financial Statements.

 

NOVO INTEGRATED SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

As of May 31, 2023 (unaudited) and August 31, 2022

 

   May 31,   August 31, 
   2023   2022 
   (unaudited)     
ASSETS          
Current Assets:          
Cash and cash equivalents  $464,011   $2,178,687 
Accounts receivable, net   1,327,613    1,017,405 
Inventory, net   938,940    879,033 
Other receivables   1,046,080    1,085,335 
Prepaid expenses and other current assets   221,414    571,335 
Total current assets   3,998,058    5,731,795 
           
Property and equipment, net   5,411,438    5,800,648 
Intangible assets, net   16,696,363    18,840,619 
Right-of-use assets, net   2,096,376    2,673,934 
Goodwill   7,542,795    7,825,844 
TOTAL ASSETS  $35,745,030   $40,872,840 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
           
Current Liabilities:          
Accounts payable  $1,896,040   $1,800,268 
Accrued expenses   1,178,245    1,116,125 
Accrued interest (including amounts to related parties)   350,831    454,189 
Government loans and notes payable, current portion   312,672    - 
Convertible notes payable, net of discount of $494,523   651,477    9,099,654 
Contingent liability   57,933    534,595 
Due to related parties   406,683    478,897 
Debentures, related parties, current portion   912,025    - 
Finance lease liability, current portion   13,814    8,890 
Operating lease liability, current portion   428,951    582,088 
Total current liabilities   6,208,671    14,074,706 
           
Debentures, related parties, net of current portion   -    946,250 
Government loans and notes payable, net of current portion   64,946    161,460 
Finance lease liability, net of current portion   -    12,076 
Operating lease liability, net of current portion   1,786,961    2,185,329 
Deferred tax liability   1,393,168    1,445,448 
TOTAL LIABILITIES   9,453,746    18,825,269 
           
Commitments and contingencies   -    - 
           
STOCKHOLDERS’ EQUITY          
Novo Integrated Sciences, Inc.          
Convertible preferred stock; $0.001 par value; 1,000,000 shares authorized; 0 and 0 shares issued and outstanding at May 31, 2023 and August 31, 2022, respectively   -    - 
Common stock; $0.001 par value; 499,000,000 shares authorized; 144,857,518 and 31,180,603 shares issued and outstanding at May 31, 2023 and August 31, 2022, respectively   144,857    31,181 
Additional paid-in capital   89,249,590    66,056,824 
Common stock to be issued (911,392 and 4,149,633 shares at May 31, 2023 and August 31, 2022, respectively)   1,217,293    9,474,807 
Other comprehensive (loss) income   (172,526)   560,836 
Accumulated deficit   (63,872,587)   (53,818,489)
Total Novo Integrated Sciences, Inc. stockholders’ equity   26,566,627    22,305,159 
Noncontrolling interest   (275,343)   (257,588)
Total stockholders’ equity   26,291,284    22,047,571 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $35,745,030   $40,872,840 

 

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

 

3
 

 

NOVO INTEGRATED SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

For the Three and Nine Months Ended May 31, 2023 and 2022 (unaudited)

 

   May 31,   May 31,   May 31,   May 31, 
   Three Months Ended   Nine Months Ended 
   May 31,   May 31,   May 31,   May 31, 
   2023   2022   2023   2022 
                 
Revenues  $3,292,933   $13,851,883   $9,268,722   $19,883,033 
                     
Cost of revenues   1,978,839    11,443,001    5,244,192    14,991,331 
                     
Gross profit   1,314,094    2,408,882    4,024,530    4,891,702 
                     
Operating expenses:                    
Selling expenses   1,877    9,802    9,916    36,340 
General and administrative expenses   2,742,635    3,601,826    9,473,802    9,542,443 
Total operating expenses   2,744,512    3,611,628    9,483,718    9,578,783 
                     
Loss from operations   (1,430,418)   (1,202,746)   (5,459,188)   (4,687,081)
                     
Non-operating income (expense)                    
Interest income   62,397    8,355    6,762    25,233 
Interest expense   (9,570)   (513,398)   (240,520)   (1,808,310)
Amortization of debt discount   (156,037)   (2,133,890)   (4,386,899)   (3,654,752)
Foreign currency transaction gain (loss)   48,333    97,654    12,652    (303,714)
Total other expense   (54,877)   (2,541,279)   (4,608,005)   (5,741,543)
                     
Loss before income taxes   (1,485,295)   (3,744,025)   (10,067,193)   (10,428,624)
                     
Income tax expense   -    -    -    - 
                     
Net loss  $(1,485,295)  $(3,744,025)  $(10,067,193)  $(10,428,624)
                     
Net loss attributed to noncontrolling interest   12,035    66,029    (13,095)   (6,816)
                     
Net loss attributed to Novo Integrated Sciences, Inc.   (1,497,330)   (3,810,054)   (10,054,098)   (10,421,808)
                     
Comprehensive loss:                    
Net loss   (1,485,295)   (3,744,025)   (10,067,193)   (10,428,624)
Foreign currency translation (loss) gain   (120,357)   13,711    (738,022)   24,916 
Comprehensive loss:  $(1,605,652)  $(3,730,314)  $(10,805,215)  $(10,403,708)
                     
Weighted average common shares outstanding – basic and diluted   143,600,541    29,817,999    85,832,252    28,498,414 
                     
Net loss per common share – basic and diluted  $(0.01)  $(0.13)  $(0.12)  $(0.37)

 

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

 

4
 

 

NOVO INTEGRATED SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

For the Three and Nine Months Ended May 31, 2023 and 2022 (unaudited)

 

   Shares   Amount   Capital   Be Issued   Income   Deficit   Equity   Interest   Equity 
   Common Stock   Additional
Paid-in
   Common
Stock To
   Other
Comprehensive
   Accumulated   Novo
Stockholders’
   Noncontrolling   Total 
   Shares   Amount   Capital   Be Issued   Income   Deficit   Equity   Interest   Equity 
Balance, August 31, 2022   31,180,603   $31,181   $66,056,824   $9,474,807   $560,836   $(53,818,489)  $    22,305,159   $(257,588)  $22,047,571 
Units issued for cash, net of offering costs   4,000,000    4,000    1,791,000    -    -    -    1,795,000    -    1,795,000 
Issuance of common stock to be issued   36,222    36    92,330    (92,366)   -    -    -    -    - 
Cashless exercise of warrants   4,673,986    4,674    1,134,376    -    -    -    1,139,050    -    1,139,050 
Fair value of stock options   -    -    60,887    -    -    -    60,887    -    60,887 
Foreign currency translation loss   -    -    -    -    (417,008)   -    (417,008)   (3,974)   (420,982)
Net loss   -    -    -    -    -    (3,935,413)   (3,935,413)   (1,323)   (3,936,736)
Balance, November 30, 2022   39,890,811   $39,891   $69,135,417   $9,382,441   $143,828   $(57,753,902)  $20,947,675   $(262,885)  $20,684,790 
                                              
Share issuance for convertible debt settlement   93,109,398    93,110    8,992,941    -    -    -    9,086,051    -    9,086,051 
Cashless exercise of warrants   1,159,348    1,159    281,374    -    -    -    282,533    -    282,533 
Exercise of warrants for cash   1,310,000    1,310    129,690    -    -    -    131,000    -    131,000 
Issuance of common stock to be issued   3,202,019    3,201    8,161,947    (8,165,148)   -    -    -    -    - 
Shares issued with convertible notes   955,000    955    82,008    -    -    -    82,963    -    82,963 
Value of warrants issued with convertible notes   -    -    86,327    -    -    -    86,327    -    86,327 
Fair value of stock options   -    -    60,887    -    -    -    60,887    -    60,887 
Extinguishment of derivative liability due to conversion   -    -    1,390,380    -    -    -    1,390,380    -    1,390,380 
Foreign currency translation loss   -    -    -    -    (195,821)   -    (195,821)   (862)   (196,683)
Net loss   -    -    -    -    -    (4,621,355)   (4,621,355)   (23,807)   (4,645,162)
Balance, February 28, 2023   139,626,576   $139,626   $88,320,971   $1,217,293   $(51,993)  $(62,375,257)  $27,250,640   $(287,554)  $26,963,086 
Share issuance for convertible debt settlement   1,075,942    1,076    99,202    -    -    -    100,278    -    100,278 
Exercise of warrants for cash   3,200,000    3,200    316,800    -    -    -    320,000    -    320,000 
Shares issued with convertible notes   955,000    955    89,177    -    -    -    90,132    -    90,132 
Value of warrants issued with convertible notes   -    -    93,811    -    -    -    93,811    -    93,811 
Beneficial conversion feature upon issuance on convertible debt   -    -    66,068    -    -    -    66,068    -    66,068 
Stock option expense   -    -    263,561    -    -    -    263,561    -    263,561 
Foreign currency translation loss   -    -    -    -    (120,533)   -    (120,533)   176    (120,357)
Net loss   -    -    -    -    -    (1,497,330)   (1,497,330)   12,035    (1,485,295)
Balance, May 31, 2023   144,857,518   $144,857   $89,249,590   $1,217,293   $(172,526)  $(63,872,587)  $26,566,627   $(275,343)  $26,291,284 
                                              
Balance, August 31, 2021   26,610,144   $26,610   $54,579,396   $9,236,607   $991,077   $(20,969,274)  $43,864,416   $(60,261)  $43,804,155 
Common stock for services   35,000    35    64,715    -    -    -    64,750    -    64,750 
Common stock issued as collateral and held in escrow   2,000,000    2,000    (2,000)   -    -    -    -    -    - 
Common stock to be issued for purchase of Terragenx   -    -    -    983,925    -    -    983,925    97,311    1,081,236 
Common stock to be issued for purchase of Mullin assets   -    -    -    188,925    -    -    188,925    -    188,925 
Value of warrants issued with convertible notes   -    -    295,824    -    -    -    295,824    -    295,824 
Fair value of stock options   -    -    154,135    -    -    -    154,135    -    154,135 
Foreign currency translation loss   -    -    -    -    (103,533)   -    (103,533)   (855)   (104,388)
Net loss   -    -    -    -    -    (1,806,587)   (1,806,587)   (9,808)   (1,816,395)
                                              
Balance, November 30, 2021   28,645,144   $28,645   $55,092,070   $10,409,457   $887,544   $(22,775,861)  $43,641,855   $26,387   $43,668,242 
Common stock for services   240,000    240    297,760    -    -    -    298,000    -    298,000 
Value of warrants issued with convertible notes   -    -    5,257,466    -    -    -    5,257,466    -    5,257,466 
Fair value of stock options   -    -    44,427    -    -    -    44,427    -    44,427 
Foreign currency translation gain   -    -    -    -    114,738    -    114,738    355    115,093 
Net loss   -    -    -    -    -    (4,805,167)   (4,805,167)   (63,037)   (4,868,204)
Balance, February 28, 2022   28,885,144   $28,885   $60,691,723   $10,409,457   $1,002,282   $(27,581,028)  $44,551,319   $(36,295)  $44,515,024 
Common stock issued for services   125,000    125    313,875    -    -    -    314,000    -    314,000 
Share issuance for convertible debt settlement   623,929    624    1,247,225    -    -    -    1,247,849    -    1,247,849 
Common stock issued for acquisition   800,000    800    1,703,200    -    -    -    1,704,000    -    1,704,000 
Common stock to be issued for acquisitions   -    -    -    260,625    -    -    260,625    25,402    286,027 
Issuance of common stock to be issued   225,000    225    573,525    (573,750)   -    -    -    -    - 
Fair value of stock options   -    -    91,330    -    -    -    91,330    -    91,330 
Foreign currency translation gain   -    -    -    -    13,711    -    13,711    51    13,762 
Net Loss                            (3,810,054)   (3,810,054)   66,029    (3,744,025)
Balance, May 31, 2022   30,659,073   $30,659   $64,620,878   $10,096,332   $1,015,993   $(31,391,082)  $44,372,780   $55,187   $44,427,967 

 

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

 

5
 

 

NOVO INTEGRATED SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

For the Nine Months Ended May 31, 2023 and 2022 (unaudited)

 

   May 31,   May 31, 
   Nine Months Ended 
   May 31,   May 31, 
   2023   2022 
         
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(10,067,193)  $(10,428,624)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization   1,718,388    2,349,434 
Fair value of vested stock options   385,335    289,892 
Common stock issued for services   -    676,750 
Financing costs for debt extension   1,421,583    - 
Operating lease expense   624,246    418,188 
Amortization of debt discount   4,386,899    3,654,752 
Foreign currency transaction (gain) loss   (12,652)   303,714 
Changes in operating assets and liabilities:          
Accounts receivable   (308,907)   (3,650,069)
Inventory   (92,260)   (263,539)
Prepaid expenses and other current assets   333,724    (150,632)
Accounts payable   154,542    117,056 
Accrued expenses   104,004    (68,871)
Accrued interest   (67,634)   598,904 
Operating lease liability   (594,618)   (406,862)
Net cash used in operating activities   (2,014,543)   (6,559,907)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of property and equipment   (18,870)   (190,973)
Cash acquired with acquisition   -    57,489 
Payments received from other receivables   -    296,138 
Net cash (used in) provided by investing activities   (18,870)   162,654 
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Repayments to related parties   (56,649)   (21,932)
Repayments of finance leases   (6,435)   (14,797)
Proceeds from (repayments of) notes payable   222,000    (4,430,794)
Proceeds from the sale of common stock, net of offering costs   1,795,000    - 
Proceeds from exercise of warrants   451,000    - 
Repayment of convertible notes   (3,033,888)   - 
Proceeds from issuance of convertible notes, net   925,306    15,270,000 
Net cash provided by financing activities   296,334    10,802,477 
           
Effect of exchange rate changes on cash and cash equivalents   22,403    (20,940)
           
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS   (1,714,676)   4,384,284 
           
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD   2,178,687    8,293,162 
           
CASH AND CASH EQUIVALENTS, END OF PERIOD  $464,011   $12,677,446 
           
CASH PAID FOR:          
Interest  $343,878   $1,294,912 
Income taxes  $-   $- 
           
SUPPLEMENTAL NON-CASH INVESTING AND FINANCING ACTIVITIES:          
Common stock issued for convertible debt settlement  $9,186,329   $1,247,849 
Common stock to be issued for intangible assets  $-   $188,925 
Common stock to be issued for acquisition  $-   $1,244,550 
Common stock issued for acquisition  $-   $1,704,000 
Beneficial conversion feature upon issuance of convertible notes  $66,068   $- 
Debt discount recognized on derivative liability  $1,390,380   $- 
Debt discount recognized on convertible note  $639,993   $- 
Extinguishment of derivative liability due to conversion  $1,390,380   $- 
Common stock issued with convertible notes  $173,095   $- 
Warrants issued with convertible notes  $180,138   $- 

 

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

 

6
 

 

NOVO INTEGRATED SCIENCES, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

For the Nine Months Ended May 31, 2023 and 2022 (unaudited)

 

Note 1 – Organization and Basis of Presentation

 

Organization and Line of Business

 

Novo Integrated Sciences, Inc. (“Novo Integrated”) was incorporated in Delaware on November 27, 2000, under the name Turbine Truck Engines, Inc. On February 20, 2008, the Company was re-domiciled to the State of Nevada. Effective July 12, 2017, the Company’s name was changed to Novo Integrated Sciences, Inc. When used herein, the terms the “Company,” “we,” “us” and “our” refer to Novo Integrated and its consolidated subsidiaries.

 

The Company owns Canadian and U.S. subsidiaries which provide, or intend to provide, essential and differentiated solutions to the delivery of multidisciplinary primary care and related wellness products through the integration of medical technology, interconnectivity, advanced therapeutics, diagnostic solutions, unique personalized product offerings, and rehabilitative science.

 

We believe that “decentralizing” healthcare, through the integration of medical technology and interconnectivity, is an essential solution to the rapidly evolving fundamental transformation of how non-catastrophic healthcare is delivered now and how it will be delivered in the future. Specific to non-critical care, ongoing advancements in both medical technology and inter-connectivity are allowing for a shift of the patient/practitioner relationship to the patient’s home and away from on-site visits to primary medical centers with mass-services. This acceleration of “ease-of-access” in the patient/practitioner interaction for non-critical care diagnosis and subsequent treatment minimizes the degradation of non-critical health conditions to critical conditions as well as allowing for more cost-effective and efficient healthcare distribution.

 

The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers:

 

  First Pillar – Service Networks: Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities.
     
  Second Pillar – Technology: Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient’s home.
     
  Third Pillar – Products: Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions.

 

On April 25, 2017 (the “Effective Date”), we entered into a Share Exchange Agreement (the “Share Exchange Agreement”) by and between (i) Novo Integrated; (ii) Novo Healthnet Limited (“NHL”), (iii) ALMC-ASAP Holdings Inc. (“ALMC”); (iv) Michael Gaynor Family Trust (the “MGFT”); (v) 1218814 Ontario Inc. (“1218814”); and (vi) Michael Gaynor Physiotherapy Professional Corp. (“MGPP,” and together with ALMC, MGFT and 1218814, the “NHL Shareholders”). Pursuant to the terms of the Share Exchange Agreement, Novo Integrated agreed to acquire, from the NHL Shareholders, all of the shares of both common and preferred stock of NHL held by the NHL Shareholders in exchange for the issuance, by Novo Integrated to the NHL Shareholders, of shares of Novo Integrated common stock such that following the closing of the Share Exchange Agreement, the NHL Shareholders would own 16,779,741 restricted shares of Novo Integrated common stock, representing 85% of the issued and outstanding Novo Integrated common stock, calculated including all granted and issued options or warrants to acquire Novo Integrated common stock as of the Effective Date, but to exclude shares of Novo Integrated common stock that are subject to a then-current Regulation S offering that was undertaken by Novo Integrated (the “Exchange”).

 

7
 

 

On May 9, 2017, the Exchange closed and, as a result, NHL became a wholly owned subsidiary of Novo Integrated. The Exchange was accounted for as a reverse acquisition under the purchase method of accounting since NHL obtained control of Novo Integrated Sciences, Inc. Accordingly, the Exchange was recorded as a recapitalization of NHL, with NHL being treated as the continuing entity. The historical financial statements presented are the financial statements of NHL. The Share Exchange Agreement was treated as a recapitalization and not as a business combination; therefore, no pro forma information is disclosed. At the closing date of the Exchange, the net assets of the legal acquirer, novo Integrated Sciences, Inc., were $6,904.

 

Impact of COVID-19

 

While all of the Company’s business units are operational at the time of this filing, any future impact of the COVID-19 pandemic on the Company’s operations remains unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced patient traffic and reduced operations. For more information regarding the impact of COVID-19 on the Company, see “Part I, Item 2, Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources—Financial Impact of COVID-19” of this quarterly report on Form 10-Q.

 

Basis of Presentation

 

The accompanying unaudited condensed consolidated financial statements were prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”) and in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. The information furnished herein reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management, are necessary to fairly state the Company’s financial position, the results of its operations, and cash flows for the periods presented. Certain information and footnote disclosures normally present in annual financial statements prepared in accordance with U.S. GAAP were omitted pursuant to such rules and regulations.

 

The financial information contained in this report should be read in conjunction with our Annual Report on Form 10-K for the fiscal year ended August 31, 2022, that the Company filed on April 3, 2023. The results of operations for the nine months ended May 31, 2023 are not necessarily indicative of the results for the fiscal year ending August 31, 2023.

 

The Company’s Canadian subsidiaries’ functional currency is the Canadian Dollar (“CAD”) and the parent company’s functional currency is the United States Dollar (“$” or “USD”); however, the accompanying unaudited condensed consolidated financial statements were translated and presented in USD.

 

Going Concern

 

The Company evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date the unaudited condensed consolidated financial statements are issued. The Company has incurred recurring losses from operations and has an accumulated deficit as at May 31, 2023. The Company believes that its cash and other available resources may not be sufficient to meet its operating needs and the payment of obligations related to various business acquisitions as they come due within one year after the date the unaudited condensed consolidated financial statements are issued.

 

To alleviate these conditions, the Company is currently in the process of raising funds through a debt financing and a subsequent public offering in the United States. As the Company’s funding activities are ongoing, there can be no assurances that the Company will be able to secure funding on terms that are acceptable to the Company, or at all. These conditions, along with the matters noted above, raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date the unaudited condensed consolidated financial statements are issued. While management has developed and is in process to implement plans that management believes could alleviate in the future the substantial doubt that was raised, management concluded at the date of the issuance of the unaudited condensed consolidated financial statements that substantial doubt exists as those plans are not completely within the control of management. These unaudited condensed consolidated financial statements do not reflect the adjustments to the carrying values of assets and liabilities and the reported expenses and consolidated balance sheets classifications that would be necessary if the Company were unable to realize its assets and settle its liabilities as a going concern in the normal course of operations. Such adjustments could be material.

 

8
 

 

Foreign Currency Translation

 

The accounts of the Company’s Canadian subsidiaries are maintained in CAD. The accounts of these subsidiaries are translated into USD in accordance with the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 830, Foreign Currency Transaction, with the CAD as the functional currency. According to Topic 830, all assets and liabilities are translated at the exchange rate on the balance sheet date, stockholders’ equity is translated at historical rates and statement of operations items are translated at the weighted average exchange rate for the period. The resulting translation adjustments are reported under other comprehensive income in accordance with ASC Topic 220, Comprehensive Income. Gains and losses resulting from the translations of foreign currency transactions and balances are reflected in the condensed consolidated statement of operations and comprehensive loss. The following table details the exchange rates used for the respective periods: 

 

   May 31, 2023   May 31, 2022   August 31, 2022 
             
Period end: CAD to USD exchange rate  $0.7351   $0.7910   $0.7627 
Average period: CAD to USD exchange rate  $0.7400   $0.7897   $0.7864 

 

Note 2 – Summary of Significant Accounting Policies

 

Use of Estimates

 

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. This applies in particular to going concern assessment, useful lives of non-current assets, impairment of non-current assets, allowance for doubtful receivables, allowance for slow moving and obsolete inventory, valuation of share-based compensation and warrants, and valuation allowance for deferred tax assets. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

 

Principles of Consolidation

 

The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and entities it controls including its wholly owned subsidiaries, NHL, Acenzia Inc. (“Acenzia”), Novomerica Health Group, Inc. (“NHG”), Novo Healthnet Rehab Limited, Novo Assessments Inc., PRO-DIP, LLC (“PRO-DIP”), a 91% controlling interest in Terragenx Inc. (“Terragenx”), a 50.1% controlling interest in 12858461 Canada Corp (“1285 Canada”), an 80% controlling interest in Novo Healthnet Kemptville Centre, Inc., a Back on Track Physiotherapy and Health Centre clinic operated by NHL, Clinical Consultants International, LLC and a 70% controlling interest in Novo Earth Therapeutics Inc. (currently inactive).

 

All intercompany transactions have been eliminated.

 

An entity is controlled when the Company has the ability to direct the relevant activities of the entity, has exposure or rights to variable returns from its involvement with the entity, and is able to use its power over the entity to affect its returns from the entity.

 

Income or loss and each component of other comprehensive income are attributed to the shareholders of the Company and to the noncontrolling interests. Total comprehensive loss is attributed to the shareholders of the Company and to the noncontrolling interests even if this results in the non-controlling interests having a deficit balance on consolidation.

 

9
 

 

Noncontrolling Interest

 

The Company follows FASB ASC Topic 810, Consolidation, which governs the accounting for and reporting of non-controlling interests (“NCIs”) in partially owned consolidated subsidiaries and the loss of control of subsidiaries. Certain provisions of this standard indicate, among other things, that NCIs be treated as a separate component of equity, not as a liability, that increases and decreases in the parent’s ownership interest that leave control intact be treated as equity transactions rather than as step acquisitions or dilution gains or losses, and that losses of a partially owned consolidated subsidiary be allocated to the NCI even when such allocation might result in a deficit balance.

 

The net income (loss) attributed to the NCI is separately designated in the accompanying condensed consolidated statements of operations and comprehensive loss.

 

Cash Equivalents

 

For the purpose of the condensed consolidated statements of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less.

 

Accounts Receivable

 

Accounts receivable are recorded, net of allowance for doubtful accounts and sales returns. Management reviews the composition of accounts receivable and analyzes historical bad debts, customer concentration, customer credit worthiness, current economic trends and changes in customer payment patterns to determine if the allowance for doubtful accounts is adequate. An estimate for doubtful accounts is made when collection of the full amount is no longer probable. Delinquent account balances are written-off after management has determined that the likelihood of collection is not probable and known bad debts are written off against the allowance for doubtful accounts when identified. As of May 31, 2023 and August 31, 2022, the allowance for uncollectible accounts receivable was $1,095,710 and $992,329, respectively.

 

Inventory

 

Inventories are valued at the lower of cost (determined by the first in, first out method) and net realizable value. Management compares the cost of inventories with the net realizable value and allowance is made for writing down their inventories to net realizable value, if lower. Inventory is segregated into three areas: raw materials, work-in-process and finished goods. The Company periodically assessed its inventory for slow moving and/or obsolete items and any change in the allowance is recorded in cost of revenues in the accompanying condensed consolidated statements of operations and comprehensive loss. If any are identified an appropriate allowance for those items is made and/or the items are deemed to be impaired. As of May 31, 2023 and August 31, 2022, the Company’s allowance for slow moving or obsolete inventory was $990,501 and $1,027,670, respectively.

 

Other Receivables

 

Other receivables are recorded at cost and presented as current or long-term based on the terms of the agreements. Management reviews the collectability of other receivables and writes off the portion that is deemed to be uncollectible. During the nine months ended May 31, 2023 and year ended August 31, 2022, the Company wrote off $nil and $299,672 (principal amount of $225,924 and accrued interest of $73,748), respectively, of other receivables that were not expected to be collected.

 

Property and Equipment

 

Property and equipment are stated at cost less depreciation and impairment. Expenditures for maintenance and repairs are charged to earnings as incurred; additions, renewals and betterments are capitalized. When property and equipment are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the respective accounts, and any gain or loss is included in operations. Depreciation of property and equipment is provided using the declining balance method for substantially all assets with estimated lives as follows:

 

Building 30 years
Leasehold improvements 5 years
Clinical equipment 5 years
Computer equipment 3 years
Office equipment 5 years
Furniture and fixtures 5 years

 

10
 

 

Leases

 

The Company applies the provisions of ASC Topic 842, Leases which requires lessees to recognize lease assets and lease liabilities on the balance sheet. The Company determines whether a contract is or contains a lease at inception of the contract and whether that lease meets the classification criteria of a finance or operating lease. When available, the Company uses the rate implicit in the lease to discount lease payments to present value; however, most of the Company’s leases do not provide a readily determinable implicit rate. Therefore, the Company must discount lease payments based on an estimate of its incremental borrowing rate.

 

Long-Lived Assets

 

The Company applies the provisions of ASC Topic 360, Property, Plant, and Equipment, which addresses financial accounting and reporting for the impairment or disposal of long-lived assets. ASC 360 requires impairment losses to be recorded on long-lived assets, including right-of-use assets, used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Loss on long-lived assets to be disposed of is determined in a similar manner, except that fair values are reduced for the cost of disposal. Based on its review at May 31, 2023, the Company believes there was no impairment of its long-lived assets.

 

Intangible Assets

 

The Company’s intangible assets are being amortized over their estimated useful lives as follows:

 

Land use rights 50 years (the lease period)
Intellectual property 7 years
Customer relationships 5 years
Brand names 7 years

 

The intangible assets with finite useful lives are reviewed for impairment when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets’ carrying amounts. In that event, a loss is recognized based on the amount by which the carrying amount exceeds the fair value of the long-lived assets. Based on its reviews at May 31, 2023, the Company believes there was no impairment of its intangible assets.

 

Right-of-use Assets

 

The Company’s right-of-use assets consist of leased assets recognized in accordance with ASC 842, Leases, which requires lessees to recognize a lease liability and a corresponding lease asset for virtually all lease contracts. Right-of-use assets represent the Company’s right to use an underlying asset for the lease term and lease liability represents the Company’s obligation to make lease payments arising from the lease, both of which are recognized based on the present value of the future minimum lease payments over the lease term at the commencement date. Leases with a lease term of 12 months or less at inception are not recorded on the condensed consolidated balance sheet and are expensed on a straight-line basis over the lease term in the condensed consolidated statements of operations and comprehensive loss. The Company determines the lease term by agreement with the lessor. In cases where the lease does not provide an implicit interest rate, the Company uses the Company’s incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.

 

Goodwill

 

Goodwill represents the excess of purchase price over the underlying net assets of businesses acquired. Under U.S. GAAP, goodwill is not amortized but is subject to annual impairment tests. The Company recorded goodwill related to its acquisition of APKA Health, Inc. (“APKA”) during the fiscal year ended August 31, 2017, Executive Fitness Leaders (“EFL”) during the fiscal year ended August 31, 2018, Action Plus Physiotherapy Rockland (“Rockland”) during the fiscal year ended August 31, 2019, Acenzia during the fiscal year ended August 31, 2021, and 1285 Canada during the fiscal year ended August 31, 2022. As of August 31, 2022, the Company performed the required impairment reviews and determined that an impairment charge of $1,357,043 related to the goodwill for Acenzia was necessary. The Company determined that the carrying value was in excess of the expected fair value of discounted cash flows based on the current market and business environments, resulting in the need for impairment. The impairment was determined based on the discounted cash flow valuation model and the projected future cash flows of the underlying business. Based on its review at May 31, 2023, the Company believes there was no additional impairment of its goodwill.

 

11
 

 

Summary of changes in goodwill by acquired businesses is as follows:

Schedule of Changes in Goodwill 

   APKA   EFL   Rockland   Acenzia   1285 Canada   Total 
Balance, August 31, 2021  $197,925   $129,839   $229,593   $8,931,491   $-   $9,488,848 
Goodwill acquired with purchase of business   -    -    -    -    602    602 
Impairment of goodwill   -    -    -    (1,357,043)   -    (1,357,043)
Foreign currency translation adjustment   (7,247)   (4,751)   (8,405)   (286,141)   (19)   (306,563)
Balance, August 31, 2022  $190,678   $